Low platelet mitochondrial complex I and complex II/III activity in early untreated parkinson's disease

PROTEIN MEASUREMENT WITH THE FOLIN PHENOL REAGENT

Lowry, O. H., Rosebrough, N., Farr, A. L., & Randall, R. (1951) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)52451-6 · Cited by 316,394

Chronic Parkinsonism in Humans Due to a Product of Meperidine-Analog Synthesis

Langston, J. W., Ballard, P., Tetrud, J. W., & Irwin, I. (1983) · Science · doi:10.1126/science.6823561 · Cited by 4,914

Mitochondrial Complex I Deficiency in Parkinson's Disease

Schapira, A. H. V., Cooper, J. M., Dexter, D., Clark, J. B., Jenner, P., & Marsden, C. D. (1990) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1990.tb02325.x · Cited by 2,283

MITOCHONDRIAL COMPLEX I DEFICIENCY IN PARKINSON'S DISEASE

Schapira, A. H. V., Cooper, J. A. D., Dexter, D. T., Jenner, P. G., Clark, J. B., & MARSDEN, C. D. (1989) · The Lancet · doi:10.1016/s0140-6736(89)92366-0 · Cited by 1,757

Abnormalities of the electron transport chain in idiopathic parkinson's disease

Parker, W. D., Boyson, S. J., & Parks, J. K. (1989) · Annals of Neurology · doi:10.1002/ana.410260606 · Cited by 1,061

Oxidative damage to mitochondrial DNA shows marked age-dependent increases in human brain

Mecocci, P., MacGarvey, U., Kaufman, A. E., Koontz, D., Shoffner, J. M., Wallace, D. C., & Beal, M. F. (1993) · Annals of Neurology · doi:10.1002/ana.410340416 · Cited by 757

CENTRAL CERVICAL CORD SYNDROME AFTER HEADING A FOOTBALL

Scoppetta, C., & Vaccario, M. L. (1978) · The Lancet · doi:10.1016/s0140-6736(78)92517-5 · Cited by 755

Deficiencies in Complex I subunits of the respiratory chain in Parkinson's disease

Mizuno, Y., Ohta, S., Tanaka, M., Takamiya, S., Suzuki, K., SATO, T. A., Oya, H., Ozawa, T., & Kagawa, Y. (1989) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(89)91141-8 · Cited by 735

Spectrophotometric Assay of Cytochrome c Oxidase

Smith, L. (1955) · Methods of biochemical analysis · doi:10.1002/9780470110188.ch13 · Cited by 506

Mitochondrial DNA Variants Observed in Alzheimer Disease and Parkinson Disease Patients

Shoffner, J. M., Brown, M. D., Torroni, A., Lott, M. T., Cabell, M. F., Mirra, S. S., Beal, M. F., Yang, C.-C., Gearing, M., Salvo, R., et al. (1993) · Genomics · doi:10.1006/geno.1993.1299 · Cited by 450

Increased oxidative stress is correlated with mitochondrial dysfunction in chagasic patients

Wen, J.-J., Yachelini, P., Sembaj, A., Manzur, R. E., & Garg, N. J. (2006) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2006.04.009 · Cited by 112

Coenzyme Q10 deficiency in patients with Parkinson's disease

Mischley, L. K., Allen, J., & Bradley, R. D. (2012) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2012.03.023 · Cited by 111

Parkinson's disease as multifactorial oxidative neurodegeneration: implications for integrative management.

Kidd, P. M. (2000) · PubMed · Cited by 110

Mitochondria: A Therapeutic Target for Parkinson’s Disease?

Luo, Y., Hoffer, A., Hoffer, B. J., & Qi, X. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms160920704 · Cited by 108

Mitochondrial function in Parkinson’s disease cybrids containing an nt2 neuron-like nuclear background

Esteves, A. R., Domingues, A. F., Ferreira, I. L., Januário, C., Swerdlow, R. H., Oliveira, C. R., & Cardoso, S. M. (2008) · Mitochondrion · doi:10.1016/j.mito.2008.03.004 · Cited by 110

Pesticides and impairment of mitochondrial function in relation with the parkinsonian syndrome

Gómez, C. (2006) · Frontiers in bioscience · doi:10.2741/2128 · Cited by 104

Mitochondria-Derived Damage-Associated Molecular Patterns in Neurodegeneration

Wilkins, H. M., Weidling, I. W., Ji, Y., & Swerdlow, R. H. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00508 · Cited by 102

Platelets in Neurodegenerative Conditions—Friend or Foe?

Leiter, O., & Walker, T. L. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00747 · Cited by 102

Neuroproteomics: Expression Profiling of the Brain's Proteomes in Health and Disease

Kim, S. I., Voshol, H., van Oostrum, J., Hastings, T. G., Cascio, M., & Glucksman, M. (2004) · Neurochemical Research · doi:10.1023/b:nere.0000023618.35579.7c · Cited by 104

Mitochondrial Dysfunction in Idiopathic Parkinson Disease

Parker, W. D., & Swerdlow, R. H. (1998) · The American Journal of Human Genetics · doi:10.1086/301812 · Cited by 97

Reappraisal of metabolic dysfunction in neurodegeneration: Focus on mitochondrial function and calcium signaling

Jadiya, P., Garbincius, J. F., & Elrod, J. W. (2021) · Acta Neuropathologica Communications · doi:10.1186/s40478-021-01224-4 · Cited by 94

Glutamate and Mitochondria: Two Prominent Players in the Oxidative Stress-Induced Neurodegeneration

Cassano, T., Pace, L., Bedse, G., Lavecchia, A. M., Marco, F. D., Gaetani, S., & Serviddio, G. (2015) · Current Alzheimer Research · doi:10.2174/1567205013666151218132725 · Cited by 96

Mitochondria-Targeted Protective Compounds in Parkinson’s and Alzheimer’s Diseases

Fernández‐Moriano, C., González‐Burgos, E., & Gómez-Serranillos, M. P. (2015) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2015/408927 · Cited by 100

Altered redox state of platelet coenzyme Q 10 in Parkinson's disease

Götz, M. E., Gerstner, A., Harth, R., Dirr, A., Janetzky, B., Kuhn, W., Riederer, P., & Gerlach, M. (2000) · Journal of Neural Transmission · doi:10.1007/s007020050003 · Cited by 93

Mitochondrial Dysfunction in Genetic Animal Models of Parkinson's Disease

Trancikova, A. K., Tsika, E., & Moore, D. J. (2011) · Antioxidants and Redox Signaling · doi:10.1089/ars.2011.4200 · Cited by 94

Transcribe to Survive: Transcriptional Control of Antioxidant Defense Programs for Neuroprotection in Parkinson’s Disease

Clark, J., & Simon, D. K. (2008) · Antioxidants and Redox Signaling · doi:10.1089/ars.2008.2241 · Cited by 93

Endoplasmic reticulum and mitochondria interplay mediates apoptotic cell death: Relevance to Parkinson's disease

Arduíno, D. M., Esteves, A. R., Cardoso, S. M., & Oliveira, C. R. (2009) · Neurochemistry International · doi:10.1016/j.neuint.2009.04.004 · Cited by 92

A possible role of coenzyme Q10 in the etiology and treatment of Parkinson's disease

Shults, C. W., Haas, R., & Beal, M. F. (1999) · BioFactors · doi:10.1002/biof.5520090223 · Cited by 91

Parkinson's Disease and Brain Mitochondrial Dysfunction: A Functional Phosphorus Magnetic Resonance Spectroscopy Study

Rango, M., Bonifati, C., & Bresolin, N. (2005) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/sj.jcbfm.9600192 · Cited by 91

Use of Cytoplasmic Hybrid Cell Lines for Elucidating the Role of Mitochondrial Dysfunction in Alzheimer's Disease and Parkinson's Disease

Ghosh, S. S., Swerdlow, R. H., Miller, S. W., Sheeman, B., Parker, W. D., & DAVIS, R. E. (1999) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1999.tb07825.x · Cited by 91

Mitochondrial Dysfunction: The Road to Alpha-Synuclein Oligomerization in PD

Esteves, A. R., Arduíno, D. M., Silva, D. F., Oliveira, C. R., & Cardoso, S. M. (2011) · Parkinson s Disease · doi:10.4061/2011/693761 · Cited by 90

Mitochondrial Dysfunction and α -Synuclein Synaptic Pathology in Parkinson’s Disease: Who’s on First?

Zaltieri, M., Longhena, F., Pizzi, M., Missale, C., Spano, P., & Bellucci, A. (2015) · Parkinson s Disease · doi:10.1155/2015/108029 · Cited by 95

A blood-based marker of mitochondrial DNA damage in Parkinson’s disease

Qi, R., Sammler, E. M., González-Hunt, C. P., Barraza, I., Pena, N., Rouanet, J. P., Naaldijk, Y., Goodson, S. D., Fuzzati, M., Blandini, F., et al. (2023) · Science Translational Medicine · doi:10.1126/scitranslmed.abo1557 · Cited by 89

The dopamine metabolite aminochrome inhibits mitochondrial complex I and modifies the expression of iron transporters DMT1 and FPN1

Aguirre, P., Urrutia, P. J., Tapia, V., Villa, M., Paris, I. B., Segura‐Aguilar, J., & Núñez, M. T. (2012) · BioMetals · doi:10.1007/s10534-012-9525-y · Cited by 89

Review: Iron metabolism and the role of iron in neurodegenerative disorders

Hadzhieva, M., Kirches, E., & Mawrin, C. (2013) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12096 · Cited by 90

Anemia or low hemoglobin levels preceding Parkinson disease: A case-control study

Savica, R., Grossardt, B. R., Carlin, J. M., Icen, M., Bower, J. H., Ahlskog, J. E., Maraganore, D. M., Steensma, D. P., & Rocca, W. A. (2009) · Neurology · doi:10.1212/wnl.0b013e3181bd80c1 · Cited by 87

Nitrosylation and nitration of mitochondrial complex I in Parkinson's disease

Chinta, S. J., & Andersen, J. K. (2010) · Free Radical Research · doi:10.3109/10715762.2010.509398 · Cited by 90

The multifaceted role of platelets in mediating brain function

Burnouf, T., & Walker, T. L. (2022) · Blood · doi:10.1182/blood.2022015970 · Cited by 86

Mitochondrial Inhibition and Oxidative Stress: Reciprocating Players in Neurodegeneration

Zeevalk, G. D., Bernard, L. P., Song, C., Gluck, M. J., & Ehrhart, J. (2005) · Antioxidants and Redox Signaling · doi:10.1089/ars.2005.7.1117 · Cited by 89

Free radical theory of aging: Alzheimer’s disease pathogenesis

Harman, D. (1995) · AGE · doi:10.1007/bf02436085 · Cited by 87

Lanosterol induces mitochondrial uncoupling and protects dopaminergic neurons from cell death in a model for Parkinson's disease

Lim, L., Jackson-Lewis, V. R., Wong, L. C., Shui, G., Goh, A. X., Kesavapany, S., Jenner, A. M., Fivaz, M. L., Przedborski, S., & Wenk, M. R. (2011) · Cell Death and Differentiation · doi:10.1038/cdd.2011.105 · Cited by 83

Mitochondrial control of cell bioenergetics in Parkinson’s disease

Requejo-Aguilar, R., & Bolaños, J. P. (2016) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2016.04.012 · Cited by 87

DJ-1 knock-down impairs astrocyte mitochondrial function

Larsen, N. J., Ambrosi, G., Mullett, S. J., Berman, S. B., & Hinkle, D. (2011) · Neuroscience · doi:10.1016/j.neuroscience.2011.08.016 · Cited by 82

Melatonin protects against neurobehavioral and mitochondrial deficits in a chronic mouse model of Parkinson's disease

Patki, G., & Lau, Y. (2011) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2011.06.026 · Cited by 81

Mitochondrial medicine for neurodegenerative diseases

Du, H., & Yan, S. S. (2010) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2010.01.004 · Cited by 82

Pre-treatment with R-Lipoic Acid Alleviates the Effects of GSH Depletion in PC12 Cells: Implications for Parkinson’s Disease Therapy

Bharath, S., Cochran, B. C., Hsu, M., Liu, J., Ames, B. N., & Andersen, J. K. (2002) · NeuroToxicology · doi:10.1016/s0161-813x(02)00035-9 · Cited by 81

Calcium, Bioenergetics, and Parkinson’s Disease

Zampese, E., & Surmeier, D. J. (2020) · Cells · doi:10.3390/cells9092045 · Cited by 79

Recent developments in the molecular genetics of mitochondrial disorders

Graeber, M. B., & Müller, U. (1998) · Journal of the Neurological Sciences · doi:10.1016/s0022-510x(97)00295-5 · Cited by 79

Coenzyme Q treatment of neurodegenerative diseases of aging

Galpern, W. R., & Cudkowicz, M. (2007) · Mitochondrion · doi:10.1016/j.mito.2007.01.004 · Cited by 78

Coenzyme Q10 a mitochondrial restorer for various brain disorders

Pradhan, N., Singh, C., & Singh, A. (2021) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-021-02161-8 · Cited by 79

Effect of coenzyme Q10 on the mitochondrial function of skin fibroblasts from Parkinson patients

Winkler‐Stuck, K., Wiedemann, F. R., Wallesch, C., & Kunz, W. S. (2004) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2004.02.003 · Cited by 77

Therapeutic role of coenzyme Q10 in Parkinson's disease

Shults, C. W. (2005) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2005.02.002 · Cited by 81

Oxidative Stress: Mechanistic Insights into Inherited Mitochondrial Disorders and Parkinson’s Disease

Shahrani, M. M. A., Heales, S., Hargreaves, I. P., & Orford, M. (2017) · Journal of Clinical Medicine · doi:10.3390/jcm6110100 · Cited by 79

Beyond Haemostasis and Thrombosis: Platelets in Depression and Its Co-Morbidities

Izzi, B., Tirozzi, A., Cerletti, C., Donati, M. B., de Gaetano, G., Hoylaerts, M., Iacoviello, L., & Gialluisi, A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21228817 · Cited by 79

Decreased NADH dehydrogenase and ubiquinol-cytochromecoxidoreductase in peripheral arterial disease

Brass, E. P., Hiatt, W. R., Gardner, A. W., & Hoppel, C. L. (2001) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.2001.280.2.h603 · Cited by 75

Mitochondria deficient in complex I activity are depolarized by hydrogen peroxide in nerve terminals: relevance to Parkinson's disease

Chinopoulos, C., & Ádám‐Vizi, V. (2001) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2001.00060.x · Cited by 73

SUMO ‐regulated mitochondrial function in Parkinson's disease

Souza, A. C. G., Prediger, R. D., & Cimarosti, H. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13599 · Cited by 78

Evidence for the toxicity of bidirectional transcripts and mitochondrial dysfunction in blood associated with small CGG expansions in the FMR1 gene in patients with parkinsonism

Loesch, D. Z., Godler, D. E., Evans, A. H., Bui, M., Gehling, F., Kotschet, K. E., Trost, N. M., Storey, E., Stimpson, P., Kinsella, G., et al. (2011) · Genetics in Medicine · doi:10.1097/gim.0b013e3182064362 · Cited by 71

The multi‐faceted role of mitochondria in the pathology of Parkinson’s disease

Trinh, D., Israwi, A. R., Arathoon, L. R., Gleave, J. A., & Nash, J. E. (2020) · Journal of Neurochemistry · doi:10.1111/jnc.15154 · Cited by 74

Succinate dehydrogenase: Prospect for neurodegenerative diseases

Farshbaf, M. J., & Kiani‐Esfahani, A. (2017) · Mitochondrion · doi:10.1016/j.mito.2017.12.002 · Cited by 71

Mitochondrial Abnormality Associates with Type-Specific Neuronal Loss and Cell Morphology Changes in the Pedunculopontine Nucleus in Parkinson Disease

Pienaar, I. S., Elson, J. L., Racca, C., Nelson, G., Turnbull, D. M., & Morris, C. M. (2013) · American Journal Of Pathology · doi:10.1016/j.ajpath.2013.09.002 · Cited by 71

Parkinson’s disease and mitochondrial complex I: a perspective on the Ndi1 therapy

Marella, M., Seo, B. B., Yagi, T., & Matsuno‐Yagi, A. (2009) · Journal of Bioenergetics and Biomembranes · doi:10.1007/s10863-009-9249-z · Cited by 69

Activity of translation regulator eukaryotic elongation factor-2 kinase is increased in Parkinson disease brain and its inhibition reduces alpha synuclein toxicity

Jan, A., Jansonius, B., Delaidelli, A., Bhanshali, F., An, Y. A., Ferreira, N., Smits, L. M., Negri, G. L., Schwamborn, J. C., Jensen, P. H., et al. (2018) · Acta Neuropathologica Communications · doi:10.1186/s40478-018-0554-9 · Cited by 66

Chronic treatment of mitochondrial disease patients with dichloroacetate

Barshop, B. A., Naviaux, R. K., McGowan, K. A., Levine, F., Nyhan, W. L., Loupis-Geller, A., & Haas, R. (2004) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2004.06.009 · Cited by 66

Mitochondrial DNA sequence variation in multiple sclerosis

Tranah, G. J., Santaniello, A., Caillier, S. J., D’Alfonso, S., Boneschi, F. M., Hauser, S. L., & Oksenberg, J. R. (2015) · Neurology · doi:10.1212/wnl.0000000000001744 · Cited by 66

Vulnerability of mesostriatal dopaminergic neurons in Parkinson’s disease

González-Hernández, T. (2010) · Frontiers in Neuroanatomy · doi:10.3389/fnana.2010.00140 · Cited by 65

Mitochondrial Importance in Alzheimer’s, Huntington’s and Parkinson’s Diseases

Correia, S. C., Santos, R. X., Perry, G. L., Zhu, X., Moreira, P. I., & Smith, M. A. (2012) · Advances in experimental medicine and biology · doi:10.1007/978-1-4614-0653-2_16 · Cited by 65

Effect of Melatonin Administration on Mitochondrial Activity and Oxidative Stress Markers in Patients with Parkinson’s Disease

Jiménez-Delgado, A., Ortíz, G. G., Delgado-Lara, D. L. C., González-Usigli, H., González-Ortiz, L. J., Cid-Hernández, M., Serrano, J. A. C., & Pacheco-Moisés, F. P. (2021) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2021/5577541 · Cited by 65

Circulating Metabolites as Potential Biomarkers for Neurological Disorders—Metabolites in Neurological Disorders

Donatti, A., do Canto, A. M., Godoi, A. B., da Rosa, D. C., & Lopes‐Cendes, Í. (2020) · Metabolites · doi:10.3390/metabo10100389 · Cited by 69

Mitochondria and α-Synuclein: Friends or Foes in the Pathogenesis of Parkinson’s Disease?

Faustini, G., Bono, F., Valerio, A., Pizzi, M., Spano, P., & Bellucci, A. (2017) · Genes · doi:10.3390/genes8120377 · Cited by 66

Gene expression profiles of the rat brain both immediately and 3 months following acute sarin exposure

Damodaran, T. V., Patel, A. G., Greenfield, S. T., Dressman, H. K., Lin, S. M., & Abou-Donia, M. B. (2005) · Biochemical Pharmacology · doi:10.1016/j.bcp.2005.10.051 · Cited by 62

Cerebral mitochondrial electron transport chain dysfunction in multiple system atrophy and Parkinson’s disease

Foti, S. C., Hargreaves, I. P., Carrington, S., Kiely, A. P., Houlden, H., & Holton, J. L. (2019) · Scientific Reports · doi:10.1038/s41598-019-42902-7 · Cited by 58

Alpha synuclein in hematopoiesis and immunity

Pei, Y., & Maitta, R. W. (2019) · Heliyon · doi:10.1016/j.heliyon.2019.e02590 · Cited by 62

Coenzyme Q10 effects in neurological diseases

Rauchová, H. (2021) · Physiological Research · doi:10.33549/physiolres.934712 · Cited by 68

Bioenergetic and proteolytic defects in fibroblasts from patients with sporadic Parkinson's disease

Ambrosi, G., Ghezzi, C., Sepe, S., Milanese, C., Payán‐Gómez, C., Bombardieri, C. R., Armentero, M., Zangaglia, R., Pacchetti, C., Mastroberardino, P. G., et al. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2014.05.008 · Cited by 60

Protective effects of asiaticoside derivatives against beta-amyloid neurotoxicity

Mook‐Jung, I., Shin, J., Yun, S. H., Huh, K., Koh, J. Y., Park, H. K., Jew, S., & Jung, M. W. (1999) · Journal of Neuroscience Research · doi:10.1002/(sici)1097-4547(19991101)58:3 · Cited by 140

Effects of Coenzyme Q10 in Huntington's disease and early Parkinson's disease

Beal, M. F., & Shults, C. W. (2003) · BioFactors · doi:10.1002/biof.5520180218 · Cited by 60

Mitochondrial preconditioning: a potential neuroprotective strategy

Correia, S. C. (2010) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2010.00138 · Cited by 58

Tetrahydrobiopterin causes mitochondrial dysfunction in dopaminergic cells: Implications for Parkinson's disease

Choi, H. J., Lee, S. Y., Cho, Y., No, H., Kim, S. W., & Hwang, O. (2005) · Neurochemistry International · doi:10.1016/j.neuint.2005.10.011 · Cited by 58

α-Synuclein amplifies cytoplasmic peroxide flux and oxidative stress provoked by mitochondrial inhibitors in CNS dopaminergic neurons in vivo

Laar, V. S. V., Chen, J., Zharikov, A., Bai, Q., Maio, R. D., Dukes, A. A., Hastings, T. G., Watkins, S. C., Greenamyre, J. T., Croix, C. M. S., et al. (2020) · Redox Biology · doi:10.1016/j.redox.2020.101695 · Cited by 56

The Neuroprotective Role of Creatine

Klein, A., & Ferrante, R. J. (2007) · Springer eBooks · doi:10.1007/978-1-4020-6486-9_11 · Cited by 56

Mitochondrial Dysfunction in Parkinson’s Disease: Focus on Mitochondrial DNA

Бунеева, О. А., Fedchenko, V. I., Kopylov, A. T., & Medvedev, A. E. (2020) · Biomedicines · doi:10.3390/biomedicines8120591 · Cited by 60

The coenzyme Q10 status of the brain regions of Parkinson’s disease patients

Hargreaves, I. P., Lane, A., & Abou‐Sleiman, P. M. (2008) · Neuroscience Letters · doi:10.1016/j.neulet.2008.09.069 · Cited by 56

Parkinson's Disease: Mitochondrial Molecular Pathology, Inflammation, Statins, and Therapeutic Neuroprotective Nutrition

KONES, R. J. (2010) · Nutrition in Clinical Practice · doi:10.1177/0884533610373932 · Cited by 57

L ‐3‐hydroxyacyl‐CoA dehydrogenase II protects in a model of Parkinson's disease

Tieu, K., Perier, C., Vila, M., Caspersen, C. S., Zhang, H., Teismann, P., Jackson-Lewis, V. R., Stern, D. M., Yan, S. D., & Przedborski, S. (2004) · Annals of Neurology · doi:10.1002/ana.20133 · Cited by 55

POLG1 polyglutamine tract variants associated with Parkinson's disease

Eerola, J., Luoma, P. T., Peuralinna, T., Scholz, S. W., Paisán‐Ruiz, C., Suomalainen, A., Singleton, A., & Tienari, P. J. (2010) · Neuroscience Letters · doi:10.1016/j.neulet.2010.04.021 · Cited by 54

Role of SIRT1/PGC-1α in mitochondrial oxidative stress in autistic spectrum disorder

Bu, X., Wu, D., Lu, X., Yang, L., Xu, X., Wang, J., & Tang, J. (2017) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s129081 · Cited by 54

Mitochondrial Sirtuins in Parkinson’s Disease

He, L., Wang, J., Yang, Y., Li, J., & Tu, H. (2022) · Neurochemical Research · doi:10.1007/s11064-022-03560-w · Cited by 55

Involvement of Mitochondria in Parkinson’s Disease

Choong, C., & Mochizuki, H. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242317027 · Cited by 58

Mitochondrial DNA polymorphisms in pathologically proven Parkinson’s disease

Bandmann, O., Sweeney, M. G., Daniel, S. E., MARSDEN, C. D., & Wood, N. W. (1997) · Journal of Neurology · doi:10.1007/s004150050082 · Cited by 53

Therapeutic attenuation of mitochondrial dysfunction and oxidative stress in neurotoxin models of Parkinson's disease

Stack, E. C., Ferro, J. L., Kim, J.-H., Signore, S. J. D., Goodrich, S., Matson, S. A., Hunt, B. B., Cormier, K., Smith, K., Matson, W. R., et al. (2008) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2007.12.006 · Cited by 53

Considerations on the role of environmental toxins in idiopathic Parkinson’s disease pathophysiology

Pan-Montojo, F. J., & Reichmann, H. (2014) · Translational Neurodegeneration · doi:10.1186/2047-9158-3-10 · Cited by 54

Metabolomics of Neurodegenerative Diseases

Botas, A., Campbell, H. M., Han, X., & Maletić‐Savatić, M. (2015) · International review of neurobiology · doi:10.1016/bs.irn.2015.05.006 · Cited by 52

Reduced platelet glutamate uptake in Parkinson's disease

Ferrarese, C., Zoia, C., Pecora, N., Piolti, R., Frigo, M., Bianchi, G., Sala, G., Begni, B., Riva, R., & Frattola, L. (1999) · Journal of Neural Transmission · doi:10.1007/s007020050189 · Cited by 51

Mitochondrial DNA–Related Mitochondrial Dysfunction in Neurodegenerative Diseases

Swerdlow, R. H. (2002) · Archives of Pathology & Laboratory Medicine · doi:10.5858/2002-126-0271-mdrmdi · Cited by 50

Oxidative stress in skin fibroblasts cultures from patients with Parkinson's disease

del Hoyo, P., García‐Redondo, A., Bustos, F., Molina, J. A., Sayed, Y., Alonso‐Navarro, H., Caballero, L., Arenas, J., Agúndez, J. A. G., & Jiménez‐Jiménez, F. J. (2010) · BMC Neurology · doi:10.1186/1471-2377-10-95 · Cited by 50

Is there a special relationship between complex I activity and nigral neuronal loss in Parkinson’s disease? A critical reappraisal

Subrahmanian, N., & LaVoie, M. J. (2021) · Brain Research · doi:10.1016/j.brainres.2021.147434 · Cited by 48

Crosstalk between Oxidative Stress and Inflammation Caused by Noise and Air Pollution—Implications for Neurodegenerative Diseases

Kuntić, M., Hahad, O., Münzel, T. F., & Daiber, A. (2024) · Antioxidants · doi:10.3390/antiox13030266 · Cited by 53

Dietary lipid concentration affects liver mitochondrial DNA copy number, gene expression and DNA methylation in large yellow croaker (Larimichthys crocea)

Liao, K., Yan, J., Mai, K., & Ai, Q. (2015) · Comparative Biochemistry and Physiology Part B Biochemistry and Molecular Biology · doi:10.1016/j.cbpb.2015.11.012 · Cited by 49

Parkinson's disease-associated pathogenic VPS35 mutation causes complex I deficits

Zhou, L., Wang, W., Hoppel, C. L., Liu, J., & Zhu, X. (2017) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2017.07.032 · Cited by 49

Genetics, drugs and environmental factors in Parkinson's disease: a case-control study

Werneck, A. L. D. S., & Alvarenga, H. (1999) · Arquivos de Neuro-Psiquiatria · doi:10.1590/s0004-282x1999000300001 · Cited by 49

Selective basal ganglia vulnerability to energy deprivation: Experimental and clinical evidences

Tambasco, N., Romoli, M., & Calabresi, P. (2018) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2018.07.003 · Cited by 48

Conditional deletion of Ndufs4 in dopaminergic neurons promotes Parkinson’s disease-like non-motor symptoms without loss of dopamine neurons

Choi, W., Kim, H.-W., Tronche, F., Palmiter, R. D., Storm, D. R., & Xia, Z. (2017) · Scientific Reports · doi:10.1038/srep44989 · Cited by 49

Role of platelet in Parkinson’s disease: Insights into pathophysiology & theranostic solutions

Beura, S. K., Panigrahi, A. R., Yadav, P., & Singh, S. K. (2022) · Ageing Research Reviews · doi:10.1016/j.arr.2022.101681 · Cited by 47

Emerging (and converging) pathways in Parkinson's disease: keeping mitochondrial wellness

Cieri, D., Brini, M., & Calí, T. (2016) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2016.08.153 · Cited by 50

Blood-based bioenergetics: An emerging translational and clinical tool

Braganza, A., Annarapu, G. K., & Shiva, S. (2019) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2019.100835 · Cited by 47

Peripheral markers of oxidative stress in Parkinson’s disease. the role of L-DOPA

Martignoni, E., Blandini, F., Godi, L., Desideri, S., Pacchetti, C., Mancini, F., & Nappi, G. (1999) · Free Radical Biology and Medicine · doi:10.1016/s0891-5849(99)00075-1 · Cited by 47

Genetic aspects of Parkinson's disease

Bandmann, O., MARSDEN, C. D., & Wood, N. W. (1998) · Movement Disorders · doi:10.1002/mds.870130203 · Cited by 47

Principles and Therapeutic Relevance for Targeting Mitochondria in Aging and Neurodegenerative Diseases

Serviddio, G., Romano, A. D., Cassano, T., Bellanti, F., Altomare, E., & Vendemiale, G. (2011) · Current Pharmaceutical Design · doi:10.2174/138161211796904740 · Cited by 45

Electron transfer complexes I and IV of platelets are abnormal in Parkinson's disease but normal in Parkinson-plus syndromes

Benecke, R., Strumper, P., & Weiss, H. (1993) · Brain · doi:10.1093/brain/116.6.1451 · Cited by 220

Abnormalities of the electron transport chain in idiopathic parkinson's disease

Parker, W. D., Boyson, S. J., & Parks, J. K. (1989) · Annals of Neurology · doi:10.1002/ana.410260606 · Cited by 1,061

Mitochondrial complex I and II activities of lymphocytes and platelets in Parkinson's disease

Yoshino, H., Nakagawa-Hattori, Y., Kondo, T., & Mizuno, Y. (1992) · Journal of Neural Transmission - Parkinsons Disease and Dementia Section · doi:10.1007/bf02257619 · Cited by 195

Platelet mitochondrial activity and pesticide exposure in early Parkinson's disease

Bronstein, J. M., Paul, K. C., Yang, L., Haas, R., Shults, C. W., Le, T. P., & Ritz, B. R. (2015) · Movement Disorders · doi:10.1002/mds.26164 · Cited by 18

PLATELET MITOCHONDRIAL-FUNCTION IN PARKINSONS-DISEASE

Krige, D., CARROLL, M., Cooper, J. A. D., MARSDEN, C., & Schapira, A. H. V. (1992) · UCL Discovery (University College London) · Cited by 12